Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Tirzepatide decreased participants’ calorie intake by reducing appetite while increasing fat oxidation. However, the drug did not decrease the slowing down of their metabolic rate usually observed ...

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

Researchers at the Pennington Biomedical Research Center have found new clues about how the drug tirzepatide, also known by ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...